A case of sudden cardiac arrest in a young adult

Zaid B. Al Jebaje, John Eligol, Robbie Wall, Osman Saleem

ABSTRACT

Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial condition that primarily affects the right ventricle. The hallmark characteristic of this disease is continual loss and replacement of normal myocardium with fibrofatty tissue. This replacement of tissue can lead to life-threatening arrhythmias and potentially sudden cardiac death (SCD). Current diagnostic modalities include, electrocardiography, family history, echocardiogram, MRI scan, angiography and myocardial biopsy.

Case Report: A 27-year-old athletic female with no known past medical history collapsed while playing frisbee in the park. Upon emergency medical service (EMS) arrival, the patient was unconscious, pulseless, and in ventricular fibrillation. After a successful resuscitation, the patient was transferred to the emergency department and admitted to the ICU. Electrocardiography revealed a QT interval of 460 milliseconds and T-wave inversion in V1, V2, and V3. Transthoracic echocardiogram revealed a left ventricular ejection fraction (LVEF) of 30% along with moderate enlargement and reduced function of the right ventricle. Genetic testing showed the patient was heterozygous for a novel variant of uncertain significance in the DSC2 gene that codes for desmosomal protein desmocollin-2. Management at this time included a wearable defibrillator for 30 days, b-blockers, and abstaining from moderate and severe physical activity. The patient then received a single chamber subcutaneous intracardiac device (ICD) and was counseled on avoiding strenuous physical exertion. Six months later, she received an implantable ICD. The patient’s first degree family members were all offered screenings.

Conclusion: This case demonstrates the complex workup involved as well as the therapeutic options for patients with ARVC. This case also highlights the importance of counseling, affected patients and unaffected carriers, as well as screening of first-degree relatives in hopes of preventing serious unwanted outcomes.
A case of sudden cardiac arrest in a young adult

Zaid B. Al Jebaje, John Elibol, Robbie Wall, Osman Saleem

ABSTRACT

Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial condition that primarily affects the right ventricle. The hallmark characteristic of this disease is continual loss and replacement of normal myocardium with fibrofatty tissue. This replacement of tissue can lead to life-threatening arrhythmias and potentially sudden cardiac death (SCD). Current diagnostic modalities include, electrocardiography, family history, echocardiogram, MRI scan, angiography and myocardial biopsy. Case Report: A 27-year-old athletic female with no known past medical history collapsed while playing frisbee in the park. Upon emergency medical service (EMS) arrival, the patient was unconscious, pulseless, and in ventricular fibrillation. After a successful resuscitation, the patient was transferred to the emergency department and admitted to the ICU. Electrocardiography revealed a QT interval of 460 milliseconds and T-wave inversion in V1, V2, and V3. Transthoracic echocardiogram revealed a left ventricular ejection fraction (LVEF) of 30% along with moderate enlargement and reduced function of the right ventricle. Genetic testing showed the patient was heterozygous for a novel variant of uncertain significance in the DSC2 gene that codes for desmosomal protein desmocollin-2. Management at this time included a wearable defibrillator for 30 days, β-blockers, and abstaining from moderate and severe physical activity. The patient then received a single chamber subcutaneous intracardiac device (ICD) and was counseled on avoiding strenuous physical exertion. Six months later, she received an implantable ICD. The patient’s first degree family members were all offered screenings. Conclusion: This case demonstrates the complex workup involved as well as the therapeutic options for patients with ARVC. This case also highlights the importance of counseling, affected patients and unaffected carriers, as well as screening of first-degree relatives in hopes of preventing serious unwanted outcomes.

Keywords: Arrhythmia, Arrhythmogenic right ventricular cardiomyopathy, Cardiomyopathy, Sudden cardiac arrest, Sudden cardiac death

INTRODUCTION

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial condition that...
primarily affects the right ventricle. The prevalence of ARVC is approximately 1 in 2000 to 1 in 5000 in the general population and generally affects men more than women at a ratio of 3:1 [1, 2]. The hallmark characteristic of this disease is continual loss and replacement of normal myocardium with fibrofatty tissue [3]. This replacement of tissue can lead to life-threatening arrhythmias and potentially sudden cardiac death (SCD). Despite the name, variations of ARVC can also affect the left side of the heart. In some cases, left-sided arrhythmias as well as left-sided heart failure may occur. Approximately 30–50% of cases of ARVC are considered familial and can be inherited in autosomal dominant or autosomal recessive forms. However, the autosomal dominant form is more common [4]. The pathogenesis is believed to be linked to over 30 genes that code for proteins involved in desmosomal structures between cardiac cells. The most known affected proteins are desmoplakin (DSP) [5], plakophilin 2 (PKP2) [6], desmoglein 2 (DSG2) [7], and desmocollin 2 (DSC2) [8]. These mutations cause a weakening in cell to cell mediated adhesions within the myocardium and lead to fibro-fatty replacement of normal ventricular tissue. Consequently, intense physical activity is restricted in these patients because of the increased risk of arrhythmia and sudden cardiac arrest/death.

What makes this diagnosis challenging is that many of the patients suffering from ARVC are young, athletic individuals, who seem overtly healthy. The most common presenting symptoms can include syncope, cardiac ischemia, arrhythmia, sudden cardiac arrest or sudden cardiac death (SCD). The original diagnostic criteria, which was established in 1994, was revised in 2010 (Table 1). In 1994, a diagnosis of ARVC had to include either 2 major, 1 major + 2 minor, or 4 minor features. When the criteria were revised in 2010, three categories were introduced. They included, definite (2 major or 1 major + 2 minor), borderline (1 major + 1 minor or 3 minor), or possible (1 major or 2 minor) features for the diagnosis of ARVC. The purpose of this revision was to increase the sensitivity of the criteria.

|--------------------------|-------------------------|
| 2 major, 1 major + 2 minor, or 4 minor | Definite = 2 major or 1 major + 2 minor  
Borderline = 1 major + 1 minor or 3 minor  
Possible = 1 major or 2 minor |

**I. Global/regional dysfunction/structural alterations**

**Major**
- Severe dilatation and reduction of RVEF with/without (or only mild) left ventricular impairment
- Localized right ventricular aneurysms (akinetically or dyskinetic areas with diastolic bulging)
- Severe segmental dilatation of the right ventricular

**Minor**
- Mild global right ventricular dilatation and/or ejection fraction reduction with normal left ventricular
- Mild segmental dilatation of the right ventricular
- Regional right ventricular hypokinesia

**By 2D echo**
- Regional right ventricular akinesia, dyskinesia, or aneurysm
- and one of the following (end diastole):
  - PLAX RVOT ≥32 mm (correct for body size [PLAX/BSA] ≥19 mm/m²)
  - PSAX RVOT ≥36 mm (correct for body size [PSAX/BSA] ≥21 mm/m²)
  - fractional area change ≤33%

**By magnetic resonance imaging scan**
- Regional right ventricular akinesia or dyskinesia or dyssynchronous right ventricular contraction
- and one of the following:
  - Ratio of right ventricular end-diastole volume (RVEDV) to body surface area (BSA) ≥110 mL/m² (male) or ≥100 mL/m² (female)
  - RV ejection fraction ≤40%

**By right ventricular angiography**
- Regional right ventricular akinesia, dyskinesia, or aneurysm

**By 2D echo**
- Regional right ventricular akinesia or dyskinesia
- and one of the following (end diastole):
  - PLAX RVOT ≥29 to <32 mm (correct body size PLAX/BSA ≥16 to <19 mm/m²)
  - PSAX RVOT ≥32 to <36 mm (correct body size [PSAX/BSA] ≥18 to <21 mm/m²)
  - fractional area change >33% to ≤40%

**By magnetic resonance imaging scan**
- Regional right ventricular akinesia or dyskinesia or dyssynchronous right ventricular contraction
- and one of the following:
  - Ratio of RVEDV to BSA ≥100 to <110 mL/m² (male) or ≥90 to <100 mL/m² (female)
  - Right ventricular ejection fraction (RVEF) >40–≤45%
II. Tissue characterization of wall

Major
- Fibrofatty replacement of myocardium on endomyocardial biopsy
- Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrosis replacement of right ventricular free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy

Minor
- Residual myocytes 60–75% by morphometric analysis (or 50–60% if estimated) with fibrous replacement of the right ventricular free wall in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy

III. Repolarization abnormalities

Major
- Inverted T-waves (V1, V2, V3) or beyond; >14 years; in absence of complete RBBB QRS ≥120 ms

Minor
- Inverted T-waves in right precordial leads (V1 and V2) (people age >12 years, in absence of RBBB)

IV. Depolarization/conduction abnormalities

Major
- Epsilon waves or localized prolongation (>110 ms) of QRS complex in right precordial leads (V1 to V3)
- Epsilon wave (reproducible low-amperic signals between the end of QRS complex to onset of T wave) in right precordial leads (V1–V3)
- Late potentials by signal-averaged electocardiogram in ≥1 of 3 parameters in absence of QRS duration of ≥110 ms on electrocardiography
  - Filtered QRS duration (fQRS) ≥114 ms
  - Duration of terminal QRS <40 µV (low amplitude signal duration) ≥38 ms
  - Root mean square voltage of terminal 40 ms ≤20 µV
- Terminal activation duration of QRS ≥55 ms measured from nadir of S wave to end of QRS, including R′ in V1, Vp or V2, in absence of complete RBBB

Minor
- Late potentials signal-averaged electrocardiogram (SAECG)
- >1000 ventricular extrasystoles per 24 hours (Holter)
- >500 ventricular extrasystoles per 24 hours (Holter)

V. Arrhythmias

Major
- NSVT or sustained ventricular tachycardia of LBBB morphology with superior access (negative or indeterminate QRS in leads II, III, and aVF and positive in lead AVL)
- NSVT or sustained ventricular tachycardia of right ventricular outflow configuration, LBBB morphology with inferior access (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
- >500 ventricular extrasystoles per 24 hours (Holter)

Minor
- LBBB sustained or NSVT (ECG, Holter, Exercise tolerance test)
- ARVC/D confirmed in false discovery rate who meets task force criteria
- ARVC/D confirmed pathologically at autopsy or surgery in false discovery rate
- Pathogenic mutation (associated or probably associated with ARVC/D) in patient under evaluation
- History of ARVC in false discovery rate in whom not possible or practical to determine if family member meets task force criteria
- Premature sudden death (<35 years) due to suspected ARVC/D in false discovery rate
- ARVC/D confirmed pathologically or by current task force criteria in second-degree relative

VI. Family History

Major
- Familial disease confirmed at necropsy or surgery
- ARVC/D confirmed in false discovery rate who meets task force criteria
- ARVC/D confirmed pathologically at autopsy or surgery in false discovery rate
- Pathogenic mutation (associated or probably associated with ARVC/D) in patient under evaluation
- History of ARVC in false discovery rate in whom not possible or practical to determine if family member meets task force criteria
- Premature sudden death (<35 years) due to suspected ARVC/D in false discovery rate
- ARVC/D confirmed pathologically or by current task force criteria in second-degree relative
and to increase the likelihood affected family members being identified before a cardiac event. The criterion was also revised in part to change in genetic testing and technological advances in medicine. If a patient survives the initial event, current diagnostic modalities include electrocardiography, family history, echocardiogram, magnetic resonance imaging scan, angiography and myocardial biopsy.

CASE REPORT

A 27-year-old athletic female with no known past medical history collapsed while playing frisbee in the park. Upon emergency medicine services (EMS) arrival, the patient was unconscious, pulseless, and in ventricular fibrillation. Cardiopulmonary resuscitation efforts were initiated and lasted 30 minutes. The patient received 8 DC shocks as well as on-scene intubation. Resuscitation attempts were successful and the patient was brought to the emergency department and transferred to the ICU.

Initial electrocardiography (Figure 1) showed a QT interval of 460 ms and T-wave inversion in V1, V2, and V3. Transthoracic echocardiogram revealed a left ventricular ejection fraction (LVEF) of 30% along with moderate enlargement and reduced function of the right ventricle. The patient was successfully extubated four days after admission. Physical examination at that time was unremarkable. Follow-up transthoracic echocardiogram revealed a preserved LVEF of 55%.

Figure 1: Electrocardiography showing T-wave inversion in V1, V2, and V3.

Cardiac catheterization was negative for coronary disease. The initial read of the cardiac MRI scan focused specifically on the left ventricle and was unremarkable. Genetic testing showed the patient was heterozygous for a novel variant of uncertain significance in the DSC2 gene that codes for desmosomal protein desmocollin-2, the pathogenic variants of which are found in autosomal dominant forms of ARVC. After the genetic study was performed, cardiac MRI scan with and without contrast (Figure 2) was read for a second time with a focus on the right ventricle. This revealed mild dilatation of the right ventricle, an elevated right ventricular end-diastolic volume index of 111 mL/m² (normal range 60–100 mL/m²), a decreased right ventricular ejection fraction of 36% (normally 60%), and no evidence of regional wall defects.

Figure 2 (A–B): Cardiac magnetic resonance imaging scan showing mild dilatation of the right ventricle, an elevated right ventricular end-diastolic volume index of 111 mL/m² (normal range 60–100 mL/m²), a decreased right ventricular ejection fraction of 36% (normally 60%), and no evidence of regional wall defects.

DISCUSSION

The diagnosis of arrhythmogenic right ventricular cardiomyopathy can be extremely challenging. This is because many patients are young and healthy adults before a symptomatic event ensues, usually precipitated by exercise. Unfortunately, by the time an event occurs, it may be too late because the most common presenting symptoms are cardiac ischemia, syncope, arrhythmia, or sudden cardiac arrest/death. ARVC accounts for 17% of cases of sudden cardiac death in the United States [9]. By definition our case represented a definitive diagnosis of ARVC due to two characteristics of the major criteria being met. This included T-wave inversion in V1–V3 with absence of right bundle branch block and mutation in desmocollin-2, which has a genetic association with ARVC [8, 10]. Restricting strenuous physical activity is imperative for both affected individuals as well as healthy genetic carriers in order to prevent exercise induced cardiac events and progression of disease [11, 12]. Additionally, clinical surveillance every two years and abstinence from intense physical activity is recommended.
in individuals with either unknown genotypes or in individuals who are known carriers of the diseases. Although there is no cure for ARVC, the name of the game is symptom management and prevention of arrhythmia or sudden cardiac death. This can be achieved with medical therapy that includes beta-blockers, diuretics, ace-inhibitors or angiotensin II receptor antagonists. Other therapies include endo/epi cardiac ablation or an intracardiac device. If these regimens prove to be suboptimal in symptom control, cardiac transplant is an alternative option. Ultimately, ARCV is a serious and complex cardiomyopathy that can result in ventricular arrhythmias and sudden cardiac death. The ARVC has an underestimated prevalence and is a challenging diagnosis that requires a high index of suspicion. Although many patients including the one discussed in this case do not show evidence of right ventricular damage, eventually all patients will. As such, diligent follow-up is imperative when treating patients with ARVC. Many aspects of ARVC have yet to be discovered and unfortunately no cure has been found to date.

CONCLUSION

This case demonstrates the complex workup involved in cases of (ARVC) as well as the therapeutic options for these patients. This case also highlights the importance of counseling, affected patients and unaffected carriers, as well as screening of first-degree relatives in hopes of preventing serious unwanted outcomes.

*********

Author Contributions

Zaid B. Al Jebaje – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

John Elibol – Substantial contributions to conception and design, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Robbie Wall – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Osman Saleem – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor of Submission

The corresponding author is the guarantor of submission.

Source of Support

None

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2017 Zaid B. Al Jebaje et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES


Edorium Journals: An introduction

About Edorium Journals
Edorium Journals is a publisher of international, high-quality, open access, scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Why should you publish with Edorium Journals?
In less than 10 words: “We give you what no one does”.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial review
All manuscripts submitted to Edorium Journals undergo pre-processing review followed by multiple rounds of stringent editorial reviews.

Peer review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early view version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates about status of your manuscripts.

Our Commitment

Six weeks
We give you our commitment that you will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Four weeks
We give you our commitment that after we receive your page proofs, your manuscript will be published in the journal within 14 days (2 weeks). If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Favored author program
One email is all it takes to become our favored author. You will not only get 15% off on all manuscript but also get information and insights about scholarly publishing.

Institutional membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in publication fees.

Our presence
We have high quality, attractive and easy to read publication format. Our websites are very user friendly and enable you to use the services easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services. Please visit: www.edoriumjournals.com

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

This page is not a part of the published article. This page is an introduction to Edorium Journals.